Tirzepatide Injection in Singapore (2025): Benefits, Eligibility, Dosing, Cost & Where to Get It

Summary (so you know where this is going)

Tirzepatide Injection is a once-weekly, prescription injection that activates GLP-1 and GIP receptors to curb appetite, slow gastric emptying, improve post-meal insulin and lower glucagon, helping weight loss and glycaemic control.

In Singapore it’s prescription-only; clinics typically start at 2.5 mg weekly and titrate up, with prices that vary by dose and provider. You’ll need doctor supervision, baseline labs, and a plan for side-effects and lifestyle

What exactly is tirzepatide?

Tirzepatide is a dual-incretin (GLP-1/GIP) agonist delivered by weekly subcutaneous injection. By combining GLP-1 and GIP signalling, it suppresses appetite, slows gastric emptying, enhances glucose-dependent insulin secretion and reduces glucagon after meals as physiology that supports weight reduction and better glucose control in type 2 diabetes. In Singapore, it’s a Prescription-Only Medicine (POM) that requires doctor evaluation and ongoing review.

Is it available in Singapore?

Yes, local clinics confirm availability and outline that it requires a medical consult and prescription. Singapore pages also describe typical initiation at 2.5 mg weekly with stepwise dose increases as tolerated and indicated.

Regulatory note. The Health Sciences Authority (HSA) lists multiple tirzepatide strengths registered locally (including 2.5 mg and higher doses) with approval entries recorded in 2025; indications include type 2 diabetes. Your doctor will advise if you’re eligible for weight management use and what documentation is needed for your case.

A 2025 review describes tirzepatide as a single-molecule treatment that activates both glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptors. Across the six SURPASS studies discussed in the review, once-weekly doses of 5 mg, 10 mg and 15 mg produced dose-dependent reductions in HbA1c and body weight in participants with type 2 diabetes.¹

Who qualifies? (Typical inclusion & exclusions doctors consider)

Potential candidates (doctor-assessed):

Adults with obesity or overweight with comorbidities (e.g., T2D, dyslipidaemia, MASLD/NAFLD, OSA), or patients with T2D needing better glycaemic and weight control despite lifestyle and first-line therapy. Some Singapore clinics also discuss metabolic benefits, including liver fat improvement, under medical supervision.

People who usually should not use tirzepatide (or need extra caution):

Pregnant or planning pregnancy; breastfeeding (discuss alternatives).
History of pancreatitis or severe GI disease; gallstone symptoms need evaluation.
Personal/family history of medullary thyroid carcinoma (MTC) or MEN2 is a red flag commonly screened for with GLP-1 class; doctors also consider local safety advisories under HSA monitoring of the GLP-1 category.

Your clinician will confirm suitability, set baseline labs (e.g., HbA1c, lipids, LFTs, eGFR) and review other medications (insulin/sulfonylureas often need dose adjustments).

Benefits you can reasonably expect

Body-weight reduction via appetite control, slower gastric emptying and hormone effects.
Improved post-meal glucose with better insulin response and lower glucagon.
Metabolic gains (e.g., triglycerides, glycaemic markers) when combined with nutrition, activity and medication review. Local clinic explainers summarise these effects for Singapore patients considering tirzepatide. Results vary by dose, time on therapy, adherence and supportive lifestyle changes.

A 2023 review of five SURPASS trials similarly reported substantial glucose lowering and weight reduction with tirzepatide, with an overall adverse-effect profile broadly comparable to that of GLP-1 receptor agonists.³ These findings came from a review of the clinical trial programme rather than a new clinical study, and the extent of response still varies between patients.

Dosing: how doctors in Singapore typically start & titrate

Most clinics introduce tirzepatide at 2.5 mg once weekly for 4 weeks, then step to 5 mg weekly, with further increases in staged intervals depending on response and tolerability. The exact maximum dose and timeline are individualised. Dose changes happen at reviews that also check side-effects, vitals and labs. Costs generally rise with higher doses, so your monthly fee may change during titration.

Missed dose rule of thumb (clinic guidance): If you remember within 4 days, take it; otherwise skip and resume the next scheduled day and don’t double-dose. Always follow your specific clinic’s instructions.

The 2025 review also noted that digestive adverse effects occurred most often during the first weeks after treatment began, supporting gradual dose escalation at four-week intervals.¹ Dose progression should still be individualised according to clinical response, tolerability and the prescribing doctor’s assessment.

How the injection works day-to-day (storage, travel, self-use)

Storage: Unopened pens are kept refrigerated (2–8 °C). After first use, many clinics allow room-temperature storage for a limited period (often up to ~21 days).
Technique: Rotate sites (abdomen, thigh, upper arm); use a clean, dry area each time; dispose of used needles in a sharp container.
These practical instructions are commonly provided by Singapore clinics initiating tirzepatide.

Side-effects & safety (and how doctors help you manage them)

The most frequent issues are nausea, vomiting, fullness/reflux, constipation which are usually transient and dose-related. Clinicians mitigate with slower titration, smaller meals, protein-forward nutrition, hydration, fibre, magnesium or stool softeners if needed. Watch for severe, persistent abdominal pain (seek urgent review as pancreatitis and gallstone disease are important rule-outs). Singapore advisories note the category-wide safety monitoring for GLP-1 agents; your provider will screen appropriately.

A 2025 single-centre audit reviewed 222 hospital admissions coded as acute or chronic pancreatitis over one year. Four patients were taking tirzepatide at admission; all four episodes were mild, while two patients had gallstones, one reported alcohol intake and one had no alternative cause identified.² Because the audit began with pancreatitis admissions and did not report the total number of people prescribed tirzepatide, it could neither estimate the incidence of pancreatitis among users nor establish that tirzepatide caused these episodes.

Where to get tirzepatide in Singapore

Medical clinics offering metabolic/weight-management services can prescribe tirzepatide after consult, labs and consent.
Hospital outpatient pharmacies dispense with valid prescriptions under the care of an attending doctor.
Singapore clinic pages outline access pathways and reinforce that tirzepatide is not over-the-counter.

What other options do I have?

Beyond tirzepatide, options include semaglutide (weekly GLP-1) and liraglutide (daily GLP-1) for appetite control and glycaemic benefits; metformin-based plans for insulin resistance/PCOS; orlistat to reduce fat absorption; and, where appropriate, prescription appetite suppressants under close supervision. Non-drug routes includes structured nutrition, resistance training, sleep/behavioural coaching with boost and sustain results. For higher BMI or multiple comorbidities, bariatric/metabolic surgery may be the most durable option. Your doctor will match the choice to your goals, health profile, and contraindications.

Tirzepatide vs semaglutide: how do Singapore clinics position them?

Singapore explainers compare both as effective incretin-based options. Some clinic pages note cost ranges (with semaglutide often lower at some doses), while choice depends on response, side-effect profile, supply and clinician experience. Discuss with your doctor which is a better fit and how to titrate.

A realistic 12-month pathway (what good care looks like)

Month 0–1 — Baseline & start

Medical history, vitals, HbA1c/lipids/LFTs/eGFR; pregnancy test where relevant.
Begin 2.5 mg weekly; set protein targets (e.g., 1.2–1.6 g/kg), fibre, hydration; schedule light-to-moderate activity (resistance + walking/NEAT).
Teach injection technique, storage, sharps disposal.

Month 2–3 — Titrate & troubleshoot

Step to 5 mg weekly if tolerated; manage nausea/constipation with meal size, timing and fibre.
Monitor weight, waist, BP, glucose and adherence.
Adjust any sulfonylurea/insulin dosing to prevent hypoglycaemia.

Month 4–6 — Consolidate

Consider higher steps if response plateaus and side-effects are mild, per doctor judgment.
Add structured resistance training (2–3×/week) to protect lean mass and help shape changes.
Recheck labs and comorbid markers (e.g., triglycerides, HbA1c).

Month 7–12 — Personalise

If goals met, consider dose maintenance; if plateau, confirm protein intake/sleep/stress and review titration or alternative agents.
Plan travel storage and missed-dose contingencies.

Cost planner: sample monthly ranges (for discussion with your clinic)

Entry-level starting doses from ~S$382 onwards per month depending on brand, strength and inclusions.

Frequently asked questions

Is tirzepatide over-the-counter?
No. It’s prescription-only; a clinician must evaluate you and supervise ongoing use.

How fast will I see results?
Appetite effects can be early; meaningful weight changes typically build across 8–12+ weeks, continuing with adherence and titration. Individual results vary.

What if I can’t tolerate nausea?
Doctors can slow titration, adjust meal patterns, consider anti-nausea strategies and review sleep/stress triggers. Many side-effects lessen after the first few weeks at each dose.

Can I take it if I have diabetes?
Yes—tirzepatide is registered for T2D; dosing and monitoring must account for other glucose-lowering drugs to avoid hypos. Your doctor will adjust medications and targets.

A 2025 clinical overview places tirzepatide within the wider management of type 2 diabetes, where a healthy diet and increased physical activity remain important and medication is added when clinically appropriate.⁴ The overview also discusses administration, dosing, potential side effects, cautions and contraindications as essential parts of safe treatment.

Does HSA have any safety updates I should know about?
HSA monitors GLP-1 agents, including the class’s internationally observed signals (e.g., rare reports of suicidal ideation). Your clinician factors local advisories into counselling and follow-up.

How should I store and travel with pens?
Keep unopened pens refrigerated; many brands allow a limited room-temperature window after first use, check your product and clinic handout. Use insulated pouches when flying; never freeze.

What happens if supply is tight?
Clinics may prioritise stable patients at current doses; costs and availability can fluctuate. Discuss plan B options and follow your clinic’s reservation or cancellation policy.

What to ask your Singapore doctor before starting

Do I qualify (BMI, comorbidities) and what baseline labs are required?
What dose will I start on, and how will we titrate?
Side-effect plan: who do I contact, and what food/supplement strategies help?
Medication interactions: do we need to adjust insulin/sulfonylureas?
Stop/step-down strategy after 6–12 months. How will we maintain results?

Final word: make tirzepatide work for you

Tirzepatide is not a magic wand and it’s a powerful tool. The best outcomes we see in Singapore pair weekly injections with:

Diet built around protein and fibre (to preserve lean mass and tame hunger).
Resistance training + NEAT (daily movement) to protect metabolism.
Adequate sleep and stress management (they influence appetite signals).
Regular reviews to titrate doses, manage side-effects and keep momentum.

If you’re ready to explore tirzepatide in Singapore, book a doctor-led assessment with us. You’ll clarify eligibility, dosing and cost, get practical injection training, and leave with a plan for nutrition, movement and follow-up that fits your life and your budget.

References

Scheen AJ. [Tirzepatide (Mounjaro®): a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes]. Revue Médicale de Liège. 2025;80(9):618–624. PMID: 40931739.
Hossain A, Fahim M, Abdalla M, et al. Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital. Cureus. 2025;17(11):e96974. doi:10.7759/cureus.96974. PMID: 41409973.
Gettman L. New Drug: Tirzepatide (Mounjaro™). The Senior Care Pharmacist. 2023;38(2):50–62. doi:10.4140/TCP.n.2023.50. PMID: 36751934.
Davies C. Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview. Nursing Standard. 2025;40(7):47–53. doi:10.7748/ns.2025.e12464. PMID: 40383978.

Want to chat?

Social